FEBS Letters · 2012 · 84 citations · 70 references
Life SciencesBiochemistryPharmacologyCell SignalingInflammationSignal TransductionAdipose TissueDiabetes MellitusInsulin ResistanceLipid MetabolismMetabolic SignalingTriglyceride MetabolismAdipocyte BiologyAdipocyte Lipid MetabolismAdipocyte MetabolismAdipose Tissue DysfunctionAdipose Tissue LipogenesisBlood Glucose RegulationDoxorubicin-based TherapyLipid Metabolism Effects
Doxorubicin-treated animals show elevated serum triglyceride and blood glucose levels. Adipocytes play an important role in buffering blood glucose and lipids. A raise in serum lipid level triggers adipogenesis in order to increase the lipid absorption capacity of adipose tissue. Doxorubicin inhibits adipogenesis through the down-regulation of PPARγ, a crucial component of the lipid metabolic pathway which controls the expression of glucose and fatty acid transporters. Doxorubicin-mediated down-regulation of PPARγ inhibits blood glucose and lipid clearance thereby causing hyperglycemia and hyperlipidemia resulting in lipotoxicity, glucotoxicity, inflammation and insulin resistance. Therefore we hypothesize that doxorubicin treatment could mimic a type 2 diabetic condition.
70
TLR4 links innate immunity and fatty acid–induced insulin resistance
Hang Shi, Maia V. Kokoeva, Karen Inouye et al. · Journal of Clinical Investigation · 2006 · 3.6K citations · Full text
Life Sciences, Immunology, Nutrition +17
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
K. Teoman Uysal, Sarah M. Wiesbrock, Michael W. Marino et al. · Nature · 1997 · 2.2K citations
Medicine, Endocrinology, Immunology +14
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Peter Tontonoz, E Hu, Reed A. Graves et al. · Genes & Development · 1994 · 2.2K citations · Full text